In this second part of a three-part of a video series, Kasey Raetz, Pharm.D., a PBMI Innovator, told MHE about leading the ...

In this final video of a three-part video series, Joshua Fredell, Pharm.D., senior vice president at CVS Caremark and a ...

Developed by Ionis Pharmaceuticals, Dawnzera is the first RNA-targeted medicine approved for HAE, designed to target plasma ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

The next step for the Rise For Health study researchers is to study the health benefits of frequent standing in older men and ...

Sexual and gender minority individuals still face insurance denials and cost-sharing barriers when accessing pre-exposure ...

The biosimilar will be available to any licensed specialty pharmacy in the United States at a 95% discount from Stelara, starting January 1, 2026.

The FDA has granted priority review of the sNDA and assigned a goal date of Dec. 20, 2025, for Imcivree to treat patients with acquired hypothalamic obesity, which is caused by an abnormality of the ...

Large language models (LLMs) were more likely to suggest inferior treatment options when reviewing hypothetical cases when ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...